CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy-Reference-Cited by-同舟云学术

CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

Published:2015-12 Issue:1 Volume:5 Page:
ISSN:2044-5040
Container-title:Skeletal Muscle
language:en
Short-container-title:Skeletal Muscle

Author:

Pinto-Mariz Fernanda,Rodrigues Carvalho Luciana,Prufer De Queiroz Campos Araujo Alexandra,De Mello Wallace,Gonçalves Ribeiro Márcia,Cunha Maria Do Carmo Soares Alves,Cabello Pedro Hernan,Riederer Ingo,Negroni Elisa,Desguerre Isabelle,Veras Mariana,Yada Erica,Allenbach Yves,Benveniste Olivier,Voit Thomas,Mouly Vincent,Silva-Barbosa Suse Dayse,Butler-Browne Gillian,Savino Wilson

Funder

PPMD

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,Orthopedics and Sports Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13395-015-0066-2

Reference31 articles.

1. Monaco A, Neve R, Colletti-Feener C, Bertelson CJ, Kurnit DM, Kunkel LM. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature. 1986;323(6089):646–50.

2. Hoffman E, Brown R, Kunkel L. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919–28.

3. Falzarano MS, Passarelli C, Ferlini A. Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy. Nucleic Acid Ther. 2014;24(1):87–100.